| Zhou, Zeping |
TE-ITP, NCT05583838: A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts |
|
|
| Completed | 4 | 157 | RoW | rhTPO, Recombinant human thrombopoietin, TPIAO, Eltrombopag, Eltrombopag olamine | Institute of Hematology & Blood Diseases Hospital, China, The Second Hospital of Hebei Medical University, Xijing Hospital, The Affiliated Hospital of Inner Mongolia Medical University, The Second Affiliated Hospital of Kunming Medical University, Second Affiliated Hospital of Guangzhou Medical University, Shaanxi Provincial People's Hospital, Henan Cancer Hospital, North China University of Science and Technology Affiliated Hospital, The Second Affiliated Hospital of Dalian Medical University, Second Hospital of Shanxi Medical University, The Second Affiliated Hospital of Harbin Medical University, Shenyang Sunshine Pharmaceutical Co., LTD., First Affiliated Hospital of Xinjiang Medical University, People's Hospital of Xinjiang Uygur Autonomous Region, Kashgar 1st People's Hospital, Xi'an Central Hospital, Beijing Public Health Foundation, Yuyao People's Hospital of Zhejiang Province | Previously Treated Primary Immune Thrombocytopenia | 02/24 | 07/24 | | |
NCT06142552: Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein |
|
|
| Recruiting | 3 | 120 | RoW | FRSW117, Recombinant human coagulation factor Ⅷ-Fc fusion protein for injection | Jiangsu Gensciences lnc. | Severe Hemophilia A | 01/26 | 09/26 | | |
NCT06312475: Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors |
|
|
| Recruiting | 3 | 51 | RoW | KN057 | Suzhou Alphamab Co., Ltd. | Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | 10/25 | 12/25 | | |
| Active, not recruiting | 3 | 194 | Europe, Canada, Japan, US, RoW | Rilzabrutinib, PRN1008, Placebo, PRN1008 Placebo | Principia Biopharma, a Sanofi Company, Principia Biopharma, Inc. | Immune Thrombocytopenia | 06/25 | 11/26 | | |
NCT06297655: A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A |
|
|
| Not yet recruiting | 3 | 60 | RoW | Recombinant human activated coagulation factor VIII for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Hemophilia A | 04/25 | 04/25 | | |
NCT06569108: Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors |
|
|
| Recruiting | 3 | 111 | RoW | KN057 | Suzhou Alphamab Co., Ltd. | Hemophilia A Without Inhibitor, Hemophilia B Without Inhibitor | 10/26 | 12/26 | | |
NCT05203679: Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug |
|
|
| Active, not recruiting | 3 | 32 | RoW | Single dose intravenous injection of BBM-H901 | Shanghai Belief-Delivery BioMed Co., Ltd | Hemophilia B | 04/24 | 06/28 | | |
CMML1-2, NCT06647862: IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia |
|
|
| Recruiting | 3 | 170 | RoW | IMM01, Timdarpacept, Azacitidine, Placebo | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Chronic Myelomonocytic Leukemia | 10/26 | 10/29 | | |
NCT06004856: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia |
|
|
| Recruiting | 3 | 195 | RoW | Orelabrutinib, Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Primary Immune Thrombocytopenia (ITP) | 12/25 | 04/26 | | |
NCT04324879: A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL) |
|
|
| Recruiting | 2 | 80 | RoW | TQ-B3525 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Relapsed / Refractory Follicular Lymphoma | 12/22 | 12/22 | | |
O-Gemox, NCT05381506: Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma |
|
|
| Not yet recruiting | 2 | 77 | RoW | Orelabrutinib and Gemox, O-Gemox | Sun Yat-sen University | DLBCL | 12/23 | 12/25 | | |
| Recruiting | 2 | 25 | RoW | STSP-0601 for Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Hemophilia | 02/25 | 02/25 | | |
NCT06092606: A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients |
|
|
| Recruiting | 2 | 90 | RoW | Control group:DH001 placebo, Control group, Trial group: DH001 low-dose group, Trial group: DH001 high-dose group | Monyan Pharmaceutical (Shanghai) Co., Ltd. | Cancer, Heart Failure, Arrhythmia, Doxorubicin Induced Cardiomyopathy, Doxorubicin Adverse Reaction | 01/25 | 01/25 | | |
NCT04202003: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) |
|
|
| Completed | 1/2 | 105 | RoW | TJ011133 | TJ Biopharma Co., Ltd. | Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes(MDS) | 12/23 | 12/23 | | |
|
|
NCT06010953: SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment |
|
|
| Completed | 1/2 | 24 | RoW | SS109 | Jiangsu Gensciences lnc. | Male, Hemophilia A With Inhibitor, Hemophilia B With Inhibitor, Hemophilia | 05/24 | 05/24 | | |
NCT05949762: Safety and Efficacy of Venetoclax in Combination With Azacitidine and HA Regimen in the Treatment of AML in the Elderly |
|
|
| Recruiting | 1/2 | 45 | RoW | Venetoclax in Combination With Azacitidine and HA Regimen | ZePing Zhou, Handan Central Hospital, Taian City Central Hospital, Tianjin People's Hospital, Guizhou Provincial People's Hospital, Second Xiangya Hospital of Central South University, Western War Zone General Hospital | Acute Myeloid Leukemia | 04/24 | 04/24 | | |
NCT06580301: Study of YK012 in B-cell Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 1/2 | 46 | RoW | YK012, YK012 for Injection | Excyte Biopharma Ltd | B-cell Acute Lymphoblastic Leukemia | 12/26 | 06/27 | | |
NCT05651061: A Phase I of SS109 in Hemophilia A or and B With Inhibitors |
|
|
| Completed | 1 | 27 | RoW | SS109 | Jiangsu Gensciences lnc. | Hemophilia A With Inhibitor, Hemophilia B With Inhibitor, Factor VII Deficiency | 03/23 | 08/23 | | |
| Guo, Yun |
| Recruiting | N/A | 10000 | RoW | NIS | Second Affiliated Hospital, School of Medicine, Zhejiang University | Psoriasis | 07/30 | 07/30 | | |
